Patent application number | Description | Published |
20080254014 | Use of Recombinant Yeast Strain Producing an Anti-Inflammatory Compound to Treat Colitis - An administration strategy is disclosed for the delivery at the intestinal mucosa of anti-inflammatory compounds, preferably acid-sensitive anti-inflammatory agents, such as IL10 and/or a soluble TNF receptor and/or trefoil factor via the oral route. In particular, inoculation with a suspension of live recombinant yeast cells, preferably | 10-16-2008 |
20080274084 | Anti-Tnf Alpha Producing Lactic Acid Bacteria for the Treatment of Chronic Enterocolitis - Treatments for chronic enterocolitis are disclosed. More specifically, methods for administration of pharmaceutical compositions that include anti-TNF-alpha antibody producing lactic acid microorganisms, such as | 11-06-2008 |
20090074734 | MICROBIAL INTESTINAL DELIVERY OF OBESITY RELATED PEPTIDES - Microbial delivery of obesity related peptides is disclosed. Genetically modified yeasts and/or lactic acid bacteria are described for the delivery of neuropeptides and/or peptide hormones that play a role in stimulation or inhibition of food intake and/or energy homeostasis. | 03-19-2009 |
20090148389 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - Induction of tolerance to antigens by mucosal, preferably oral, delivery of the antigen in combination with an immunomodulating compound producing micro-organism is disclosed. More specifically, Foxp3 | 06-11-2009 |
20100104601 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENTS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 04-29-2010 |
20100172920 | METHOD OF INDUCING IMMUNE TOLERANCE TO TYPE I DIABETES - A method for inducing immune tolerance to type I diabetes in a mammal by mucosal delivery of an antigen involved in the induction of type I diabetes such as pro-insulin or insulin is disclosed. The antigen involved in the induction of type I diabetes is delivered together with an IL-10 secreting micro-organism such as | 07-08-2010 |
20100178273 | METHODS AND COMPOSITIONS FOR TREATING MUCOSITIS - The invention relates generally to the field of mucositis. More particularly, the present invention relates to methods and compositions for treating and preventing mucositis. In particular for treating or preventing oral mucositis, especially stomatitis and esophagitis. The invention generally relates to the use of recombinant non-pathogenic and non-invasive microorganisms, in particular recombinant bacterium or yeast expressing a trefoil peptide in particular in combination with one or more factors that target the mucus, tight junctions or extracellular matrix and/or factors typically used in the treatment of mucositis. | 07-15-2010 |
20100303777 | DELIVERY OF BINDING MOLECULES TO INDUCE IMMUNOMODULATION - Delivery of binding molecules, such as antibodies, antibody fragments, single antibody variable domains, soluble receptors, ligands and dominant negative variants, to induce an immunomodulation in a patient is disclosed. More specifically, a medicament which includes micro-organisms which produce the binding molecules is described for the treatment of immune mediated diseases. | 12-02-2010 |
20130095129 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 04-18-2013 |
20130330374 | TREATMENT OF IMMUNE DISEASE BY MUCOSAL DELIVERY OF ANTIGENS USING GENETICALLY MODIFIED LACTOBACILLUS - The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular | 12-12-2013 |
20140322230 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3 | 10-30-2014 |
20140322266 | INDUCTION OF MUCOSAL TOLERANCE TO ANTIGENS - The present invention relates to the induction of tolerance to antigens, by mucosal, preferably oral delivery of the antigen in combination with an immunomodulating compound producing micro-organism. More specifically, the invention relates to the induction of Foxp3 | 10-30-2014 |